T0	Participants 0 83	Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma:
T1	Participants 231 368	patients with resected renal cell carcinoma (RCC) at high risk for recurrent disease (TNM stages III and IV resected distant metastases).
T2	Participants 390 473	Patients with surgically resected locally advanced (T3-4 or N1-2) or metastatic RCC
T3	Participants 1081 1161	Forty-one patients were entered in the study and 40 were evaluable for toxicity.
T4	Participants 2136 2201	patients with surgically resected RCC at high risk of recurrence.